Last line therapy with sorafenib in colorectal cancer: A retrospective analysis

Table 1 Patient characteristics

Patient characteristics	n (%)
Total number	10.0
Average age (yr)	65.4
Gender
Female	2 (20)
Male	8 (80)
Location
Colon	8 (80)
Rectum	2 (20)
UICC
1 + 2 + 3	0 (0)
4	10 (100)
Metastases
Liver	6 (60)
Lung	8 (80)
Lymph nodes	5 (50)
Prior ctx regimen
3	7 (70)
4	2 (20)
5	0 (0)
6	1 (10)

Table 2 Detailed description of patients at therapy start

Patient	Age	Gender	Primary	UICC	Liver metastases	Lunge metastases	Number of pre-therapies
1	68	M	Sigma	IV	1	1	3
2	52	M	Colon desc.	IV	0	1	3
3	51	M	Sigma	IV	1	1	3
4	81	M	Rectum	IV	1	1	3
5	59	F	Colon desc.	IV	1	1	3
6	74	M	Sigma	IV	0	1	3
7	74	M	Rectum	IV	1	0	4
8	65	F	Sigma	IV	1	1	6
9	69	M	Sigma	IV	0	1	3
10	61	M	Colon desc.	IV	0	0	4

Table 3 Detailed treatment description of patients

Pt.	Comb. partner	6-wk		12-wk		PFS (d)	OS (d)
		Response	% change	Response	% change
1	5-FU	SD	-13%	SD	-7%	144	165
2	None	0	0	0	0	21	21
3	TU	SD	12%	0	0	791	163
4	5-FU	PD	35%	0	0	41	382
5	C	SD	-6%	PD	32%	149	302
6	TU	SD	-2%	0	0	322	113
7	C	SD	-21%	SD	5%	137	188
8	C	SD	-4%	PD	24%	199	296
9	C	SD	3%	PD	32%	177	147
10	TU	SD	5%	SD	6%	188	447

¹Treatment stop due to bleeding complication;

²Treatment stop due to sorafenib allergy. TU: Tegafur Uracil; C: Capecitabine; SD: Stable disease; PD: Progressive disease; PFS: Progression free survival.

Table 4 Adverse events (CTC AE3.0)

Patient	I°-II°	III°-IV°	Total
Fatigue	70% (7/10)	30% (3/10)	100%
Nausea	20% (2/10)	0% (0/10)	20%
Emesis	20% (2/10)	10% (1/10)	30%
Diarrhea	40% (4/10)	0% (0/10)	40%
Mukositis	30% (3/10)	10% (1/10)	40%
Rash	20% (2/10)	0% (0/10)	20%
HFS	30% (3/10)	0% (0/10)	30%
PNP	20% (2/10)	0% (0/10)	20%
Pain	20% (2/10)	10% (1/10)	30%
Weight loss	10% (1/10)	0% (0/10)	10%
Infection	20% (2/10)	0% (0/10)	20%
Anemia	40% (4/10)	20% (2/10)	60%
Thrombopenia	30% (3/10)	10% (1/10)	40%
Leucopenia	20% (2/10)	10% (1/10)	30%